CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

BOCA PHARMACAL INC

BOCA PHARMACAL INC is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pherin Pharmaceuticals Inc

Pherin Pharmaceuticals Inc is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rogers Group

Headquartered in Nashville, Tennessee, Rogers Group Inc. provides crushed stone, sand and gravel, asphalt and highway construction to the southeastern United States. In 2009, the company was listed as the ninth largest aggregates producer in the nation...

Cary Pharmaceuticals Inc

Cary Pharmaceuticals Inc is a Great Falls, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Topigen Pharmaceuticals